Compare Hyloris Pharmaceuticals SA with Similar Stocks
Dashboard
1
Weak Long Term Fundamental Strength with an average Return on Equity (ROE) of 0%
- Poor long term growth as Operating profit has grown by an annual rate 0.35% of over the last 5 years
- Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -11.97
2
Flat results in Jun 25
3
Risky -
4
Consistent Underperformance against the benchmark over the last 3 years
Stock DNA
Pharmaceuticals & Biotechnology
EUR 161 Million ()
NA (Loss Making)
NA
0.00%
-0.47
-22.33%
5.56
Revenue and Profits:
Net Sales:
0 Million
(Quarterly Results - Jun 2020)
Net Profit:
-2 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-6.78%
0%
-6.78%
6 Months
-8.03%
0%
-8.03%
1 Year
-12.7%
0%
-12.7%
2 Years
-51.33%
0%
-51.33%
3 Years
-57.03%
0%
-57.03%
4 Years
-68.12%
0%
-68.12%
5 Years
-52.26%
0%
-52.26%
Hyloris Pharmaceuticals SA for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
30.55%
EBIT Growth (5y)
0.35%
EBIT to Interest (avg)
-11.97
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.62
Sales to Capital Employed (avg)
0.09
Tax Ratio
9.58%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
6.34
EV to EBIT
-22.51
EV to EBITDA
-24.63
EV to Capital Employed
11.09
EV to Sales
23.15
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-49.25%
ROE (Latest)
-22.33%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Mildly Bullish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
Mildly Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
8.50
2.10
304.76%
Operating Profit (PBDIT) excl Other Income
-7.00
-17.60
60.23%
Interest
0.10
0.10
Exceptional Items
0.10
-0.20
150.00%
Consolidate Net Profit
-6.30
-15.40
59.09%
Operating Profit Margin (Excl OI)
-905.80%
-8,611.90%
770.61%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 304.76% vs 133.33% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 59.09% vs -29.41% in Dec 2023
About Hyloris Pharmaceuticals SA 
Hyloris Pharmaceuticals SA
Pharmaceuticals & Biotechnology
Hyloris Pharmaceuticals is a Belgium-based specialty pharmaceutical company. Its focus is on re-engineering cardiovascular products. Additionally, it also further develops and improves already-approved pharmaceuticals and established products, creating new and different solutions. The Company’s diverse product-development portfolio spans a wide range of therapeutic indications and dosage forms.
Company Coordinates 
Company Details
Boulevard Gustave Kleyer 17 , LIEGE None : 4000
Registrar Details






